Clinical outcomes in patients with faster advancing MS treated with teriflunomide in TEMSO and TOWER

被引：0
|
作者：
Kappos, L. [1 ]
Thangavelu, K. [2 ]
Cavalier, S. [2 ]
Truffinet, P. [3 ]
Comi, G. [4 ]
Miller, A. [5 ]
机构：
[1] Univ Hosp Basel, Basel, Switzerland
[2] Sanofi Genzyme, Cambridge, MA USA
[3] Sanofi Genzyme, Chilly Mazarin, France
[4] Univ Vita Salute San Raffaele, Milan, Italy
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P11185
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [41] Pregnancy outcomes in patients treated with leflunomide, an in vivo precursor of the multiple sclerosis drug teriflunomide
    Truffinet, P.
    Afsar, S.
    Davenport, L.
    Purvis, A.
    Poole, E. M.
    Henson, L. J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 621 - 621
  • [42] A Subgroup Analysis of the Phase 3 TOWER Study Assessing Efficacy and Safety of Teriflunomide in Asian Patients with Relapsing Forms of MS
    Macdonell, R.
    Freedman, M. S.
    Xu, X.
    Vucic, S.
    Truffinet, P.
    Benamor, M.
    Thangavelu, K.
    Miller, A. E.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 402 - 402
  • [43] Real world clinical and imaging outcomes in relapsing ms patients treated with alemtuzumab in a us regional ms center
    Khatri, B.
    Murphy, C.
    Sershon, L.
    Olapo, O.
    Perea, T.
    Beals, S.
    Lindman, L.
    Poole, E.
    Robinson, R.
    Patel, A.
    Gandhi, R.
    Hashemi, L.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 185 - 185
  • [44] Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience
    Vukusic, Sandra
    Coyle, Patricia K.
    Jurgensen, Stephanie
    Truffinet, Philippe
    Benamor, Myriam
    Afsar, Salman
    Purvis, Annie
    Poole, Elizabeth M.
    Chambers, Christina
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (07) : 829 - 836
  • [45] Reduced risk of disability progression in patients with MS treated with early vs delayed teriflunomide 14 mg
    O'Connor, P. W.
    Wolinsky, J. S.
    Thangavelu, K.
    Truffinet, P.
    Rufi, P.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 255 - 255
  • [46] MRI Outcomes in Patients With Early Multiple Sclerosis Treated With Teriflunomide: Results From the TOPIC Study
    King, J.
    Miller, A. E.
    Taylor, B.
    Macdonell, R.
    Shaw, C.
    Truffinet, P.
    Bauer, D.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 820 - 821
  • [47] Clinical and radiological outcomes among MS patients treated with Alemtuzumab and Ocrelizumab: a Real World Experience
    Zito, A.
    Polidoro, F.
    Neo, C.
    Rigoni, E.
    Singh-Curry, V.
    Nandoskar, A.
    Dorsey, R.
    Bergamaschi, R.
    Muraro, P. A.
    Nicholas, R.
    Scalfari, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 171 - 172
  • [48] Effect of teriflunomide on MRI activity in patients with early MS: outcomes from the phase 3 TOPIC study
    Wolinsky, J. S.
    Comi, G.
    Kappos, L.
    Bauer, D.
    Truffinet, P.
    Miller, A. E.
    JOURNAL OF NEUROLOGY, 2014, 261 : S75 - S75
  • [49] Effect of teriflunomide on MRI activity in patients with early MS: outcomes from the phase 3 TOPIC study
    Wolinsky, J. S.
    Comi, G.
    Kappos, L.
    Bauer, D.
    Truffinet, P.
    Miller, A. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 103 - 103
  • [50] Clinical Outcomes And Treatment Satisfaction In Patients Switching To Teriflunomide In The Real-world Teri-PRO And TAURUS-MS I Studies
    Freedman, M. S.
    Kallmann, B. A.
    Meca-Lallana, J. E.
    Khatri, B.
    Inshasi, J. S.
    Kim, B. J.
    Rufi, P.
    Benamor, M.
    Truffinet, P.
    Poole, E. M.
    Coyle, P. K.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 137 - 137
12345